Zoetis Inc. (NYSE:ZTS) Stock Position Decreased by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,020 shares of the company’s stock after selling 107 shares during the quarter. Zoetis accounts for 1.1% of Tokio Marine Asset Management Co. Ltd.’s portfolio, making the stock its 17th largest holding. Tokio Marine Asset Management Co. Ltd.’s holdings in Zoetis were worth $20,333,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the stock. Atria Wealth Solutions Inc. boosted its stake in shares of Zoetis by 4.0% during the 4th quarter. Atria Wealth Solutions Inc. now owns 16,618 shares of the company’s stock worth $3,280,000 after acquiring an additional 643 shares in the last quarter. NewSquare Capital LLC bought a new stake in shares of Zoetis during the 4th quarter worth $69,000. GAMMA Investing LLC bought a new stake in shares of Zoetis during the 4th quarter worth $975,000. Parkside Financial Bank & Trust boosted its position in shares of Zoetis by 20.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,912 shares of the company’s stock worth $377,000 after buying an additional 325 shares during the period. Finally, SlateStone Wealth LLC boosted its position in shares of Zoetis by 2.2% in the fourth quarter. SlateStone Wealth LLC now owns 26,071 shares of the company’s stock worth $5,146,000 after buying an additional 571 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 0.9 %

ZTS traded up $1.33 during trading on Wednesday, reaching $150.89. 3,640,337 shares of the stock traded hands, compared to its average volume of 3,074,906. The stock has a market cap of $69.01 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.85. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock’s 50-day simple moving average is $173.11 and its two-hundred day simple moving average is $179.58.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the business posted $1.15 EPS. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ZTS shares. The Goldman Sachs Group raised their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Stifel Nicolaus decreased their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $218.00.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 2,209 shares of company stock worth $371,293 over the last three months. Corporate insiders own 0.15% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.